erlotinib hydrochloride has been researched along with Signet Ring Cell Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Masago, K; Mishima, M; Miura, M; Togashi, Y; Toyama, Y | 1 |
1 other study(ies) available for erlotinib hydrochloride and Signet Ring Cell Carcinoma
| Article | Year |
|---|---|
Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma, Signet Ring Cell; DNA Mutational Analysis; Epidermal Growth Factor; Erlotinib Hydrochloride; Exons; Female; Humans; Immunohistochemistry; Mutation; Polymerase Chain Reaction; Quinazolines; Thyroid Neoplasms | 2011 |